SABS Stock Summary and Trading Ideas (Sab Biotherapeutics | NASDAQ:SABS)

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

What symbol and exchange does Sab Biotherapeutics shares trade?

Sab Biotherapeutics trades on the NASDAQ stock market under the symbol SABS.

What is Sab Biotherapeutics stock price doing today?

As of December 26, 2025, SABS stock price declined to $3.78 with 62,807 million shares trading.

What is Sab Biotherapeutics's Beta?

SABS has a beta of 1.69, meaning it tends to be more sensitive to market movements. SABS has a correlation of 0.08 to the broad based SPY ETF.

How much is Sab Biotherapeutics worth?

SABS has a market cap of $179.95 million. This is considered a Micro Cap stock.

How much money does Sab Biotherapeutics make?

Last quarter Sab Biotherapeutics reported $0 in Revenue and -$.21 earnings per share. This fell short of revenue expectation by $-249,998 and exceeded earnings estimates by $.30.

What is the highest and lowest price Sab Biotherapeutics traded in the last 3 year period?

In the last 3 years, SABS traded as high as $14.50 and as low as $1.00.

What are the top ETFs holding Sab Biotherapeutics?

The top ETF exchange traded funds that SABS belongs to (by Net Assets): VTI, VXF, AVSC.

Is Sab Biotherapeutics (SABS) a good investment?

SABS has underperformed the market in the last year with a return of -7.8%, while SPY returned +16.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SABS shares. However, SABS has outperformed the market in the last 3 month and 2 week periods, returning +75.0% and +1.9%, while SPY returned +4.7% and +0.7%, respectively. This indicates SABS has been having a stronger performance recently.

What are the support and resistance levels for Sab Biotherapeutics (SABS)?

SABS support price is $3.66 and resistance is $4.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SABS shares will trade within this expected range on the day.